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Abstract
This review discusses using yeast as a model organism for studying the biologi-
cal effects of P450-mediated metabolism of xenobiotics. We discuss the challenges 
of testing the safety of thousands of chemicals currently introduced into the 
market place, the limitations of the animal systems, the advantages of model organ-
isms, and the humanization of the yeast cells by expressing human cytochrome 
P450 (CYP) genes. We discuss strategies in utilizing multiple genetic endpoints in 
screening chemicals and yeast strains that facilitate phenotyping CYP polymor-
phisms. In particular, we discuss yeast mutants that facilitate xenobiotic import 
and retention and particular DNA repair mutants that can facilitate in measuring 
genotoxic endpoints and elucidating genotoxic mechanisms. New directions in 
toxicogenetics suggest that particular DNA damaging agents may interact with 
chromatin and perturb gene silencing, which may also generate genetic instabili-
ties. By introducing human CYP genes into yeast strains, new strategies can be 
explored for high-throughput testing of xenobiotics and identifying potent DNA 
damaging agents.
Keywords: cytochrome P450 polymorphisms, genotoxins, budding yeast, 
recombination assays
1. Introduction
Genotoxins are generally referred to as chemical agents that cause DNA dam-
age, which, in turn, can initiate recombination or mutation events or chromosome 
loss [1]. While mutagens and recombinagens are genotoxic, not all genotoxins are 
directly mutagenic [2]. Genotoxic exposure has been correlated to birth defects [3], 
cardiovascular disease [4], carcinogenesis [5], and accelerated aging [6]. Public 
health depends on minimizing exposure to genotoxic chemicals. Nonetheless, 
thousands of chemicals have yet to be tested, and new chemicals are annually 
synthesized. Federal agencies mandate that all chemicals be tested for safety before 
being introduced into the marketplace [7]. Generally, this testing has involved 
rapid screens for bacterial mutagenesis, micronuclei assays or comet assays for 
testing DNA fragmentation, and animal testing for determining carcinogenicity. 
Animal testing is often expensive and time-consuming and has increasingly raised 
ethical concerns. While microbial plate assays, such as the Ames test [8], have been 
standard in identifying chemical mutagens, some chemicals that test negative in 
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the Ames assays are carcinogenic, while others that test positive in the Ames assays 
are not carcinogens [8, 9]. Many chemicals are not genotoxic per se but require 
metabolic bioactivation [10]. The bioactivated compound is generally a highly 
reactive intermediate in a pathway which renders hydrophobic compounds more 
hydrophilic to facilitate excretion. While bioactivation does occur in specific animal 
models, toxicity outcomes differ depending on the species [11]. Thus, there is a 
need for metabolic competent cell-based assays that can measure multiple genotoxic 
endpoints.
Bioactivation occurs by phase I and phase II enzymes; phase I enzymes generally 
hydroxylate compounds so that phase II enzymes can conjugate larger molecules, 
facilitating the export and excretion of the modified compound. Phase I enzymes 
include cytochrome P450 monooxygenases (CYPs), which compose a superfamily 
of over 50 genes, and catalyze the formation of highly reactive electrophiles and 
epoxides, as intermediates in xenobiotic metabolism [12, 13]. Up to 80% of all 
bioactivations require CYPs [14]. For catalytic efficiency, the CYP proteins must be 
reduced by oxidoreductases, which are colocalized with CYPs in the endoplasmic 
reticulum (ER [15]).
Saccharomyces cerevisiae (budding yeast) is an excellent eukaryotic model organ-
ism for studying the genotoxicity of xenobiotics, including pharmaceuticals, pesti-
cides, insecticides, and suspected carcinogens. Similar to bacterial organisms, yeast 
strains are easy to culture, grow rapidly, and can be manipulated genetically, render-
ing it possible to perform high-throughput analysis [16]. Many yeast genes are similar 
to human genes, and approximately 30% of can be functionally replaced by the 
human orthologue [17, 18]. DNA repair pathways and genes are also similar [17, 16]. 
Mitochondrial genotoxicity can also be measured [19]. Thus, identifying genotoxins 
and understanding their mechanisms in budding yeast can elucidate whether similar 
mechanisms occur in human cells.
However, yeasts also have some disadvantages. First, yeast cells contain a cell 
wall that blocks entry to carcinogens, and higher chemical concentrations are 
required in yeast than in mammalian organisms to observe similar genotoxic 
endpoints [1, 20]. Second, yeast lacks some functions of mammalian cells; while 
there are many yeast genes that have human homologs, other human DNA repair 
genes, such as p53, BRCA1, and BRCA2, have no corresponding yeast homologs. 
Nonetheless, the ability to modify the yeast genome has enabled yeast biologists to 
enhance carcinogen uptake and retention in cells [20, 21].
Engineered yeast strains enable high-throughput screens for identifying 
genotoxins among the thousands of novel synthetic chemicals, circumventing 
the limitations and reducing the escalating costs of animal tests. By expressing 
specific human cytochrome P450 genes in the engineered strains, tissue-specific 
metabolic activation can be simulated. Besides identifying genotoxins, engineered 
yeast strains can elucidate genotoxic mechanisms by measuring multiple genetic 
alterations, as well as DNA and organelle damage. Future engineering of yeast 
strains may identify additional human metabolic genes that can confer resistance to 
P450-activated genotoxins.
This review will address (1) characterization of human CYPs that activate 
the majority of carcinogens, (2) yeast vectors that have been engineered to 
express these CYPs, (3) plate and reporter assays that have been used to detect 
CYP-dependent activated compounds in yeast, (4) chemicals which have been 
identified and mechanistic insights that have been garnered by utilizing yeast 
genetics, (5) studies that have phenotypes P450 polymorphisms, (6) compari-
sons with other model eukaryotes, and (7) future directions in guiding geno-
toxic assays.
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2. Phase I and phase II enzymes that bioactivate xenobiotics
While 57 CYPs have been identified, approximately 80% of all bioactivation 
is mediated by just 7 CYPs: CYP1A1, 1A2, 1B1, 2A13, 2A6, 2E1, and 3A4 [22]. 
Xenobiotic chemicals that are activated by these CYPs include polycyclic aromatic 
hydrocarbons (PAHs), aryl- and heterocyclic amines (HAAs), and nitrosamines, as 
well as small molecules such as benzene, naphthalene, and furans [22]. Examples 
of CYP-activated xenobiotics include tobacco carcinogens, industrial solvents, and 
food carcinogens, including the most potent liver carcinogen, aflatoxin B1 (AFB1). 
The importance of individual CYPs is underscored by observations that particular 
knockout mice are more resistant to environmental carcinogens, for example, 
fewer tumors arise in Cyp1b1−/− and Cyp2a5 −/− knockout mice after exposure to 
7,12-dimethylbenz[a]anthracene [23] and 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) [24], respectively.
Phase II enzymes include glutathione S-transferases, N-acetyl transferases, 
epoxide hydrolases, glucuronidases, and sulfotransferases. They serve to both 
inactivate highly reactive intermediates that are formed by phase I enzymes and 
conjugate larger molecules onto the products of phase I reactions to facilitate export 
and excretion [25]. While some phase II enzymes, such as glutathione S-transferases 
(GSTs), may inactivate epoxide intermediates, other phase II enzymes, such as 
N-acetyl transferases (NATs), may facilitate the conversion of hydroxylated het-
erocyclic aromatic amines to highly nitrenium ions (Figure 1 [25]). For example, 
2-amino-3-methylimidazo[4,5-f]quinoline (IQ ) is hydroxylated by CYP1A2 in 
the liver [26]. Further modification by NAT2 acetylates the hydroxylated product, 
resulting in an unstable intermediate yielding a reactive nitrenium ion; this nitre-
nium ion reacts with DNA yielding deoxyguanine DNA adducts [25, 26]. Pathways 
by which activated HAAs drive colon carcinogenesis are unclear. One notion is that 
reactive IQ metabolites can also be glucuronidated in the liver and excreted into 
Figure 1. 
Phase 1 and phase 2 metabolism of IQ. CYP1A2 generates the formation of N-hydroxy IQ. NAT2 generates an 
unstable molecule, N-acetoxy-IQ , which then generates a reactive nitrenium ion. The reactive nitrenium ion 
interacts with DNA to form adducts, particularly at the C8 and C2 positions of guanine. Figure was adapted 
from Kim and Guengerich [25].
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the colon. Gut microbial glucuronidases then cleave the glucose and reactivate the 
compound leading to genotoxicity in the colon [27]. An alternative notion is that IQ 
is bioactivated to a mutagen in situ in the colon. Expression of multiple mammalian 
phase I and phase II enzymes may be important in rendering some compounds 
genotoxic; examples include CYP1A1 and epoxide hydrolase in the activation of 
benzo[a]pyrene and CYP2E1 and SULT1A1 for the activation of 2,5-dimethylfuran 
(DMF) and furfuryl alcohol (FFA) [5, 22].
When compounds are substrates for multiple CYPs or phase II enzymes, 
products of varying toxicity can be generated; examples of substrates include 
estradiol, N-acetyl-p-aminophenol (APAP or acetaminophen), and AFB1. In the 
case of estradiol, CYP1A2 and CYP3A4 predominately hydroxylate estradiol in the 
2′ position generating 2′ hydroxyestradiol [28, 29], while CYP1B1 hydroxylates 
estradiol in the 4′ position generating 4′ hydroxyestradiol; further modification 
of 4′-hydroxyestradiol by peroxidases generates a highly reactive form that gener-
ates DNA adducts, while 2′ hydroxylestradiol can be detoxified [29]. In the case 
of acetaminophen, most acetaminophen is converted to nontoxic forms by sulfo-
transferases and glucuronidases; CYP2E1 converts acetaminophen to N-acetyl-p-
benzoquinone imine (NAPQI), which depletes glutathione levels, causes oxidative 
stress, and is highly toxic in the liver [30]. Since CYP2E1 is induced by alcohol, the 
combination of alcohol and acetaminophen can be lethal [29]. Regarding AFB1, 
AFB1 is metabolized by CYP1A2 and CYP3A4 into a toxic epoxide intermediate, 
while the extrahepatic CYP1A1 can also convert AFB1 to AFM, which is still geno-
toxic but not as carcinogenic [31]. Because expression and inducibility of CYPs vary 
among individuals and multiple CYPs are expressed in tissues, it can be difficult to 
identify which CYP(s) generates the activated genotoxin.
Yeast presents advantages in deciphering which human CYPs can metabolize 
genotoxins. First, the three endogenous yeast CYPs largely function to synthesize 
ergosterol or dityrosine synthesis [32, 33]. Second, expression of CYPs in yeast can 
be regulated by inducible promoters or by copy number, mitigating potential toxic 
effects of their expression [34, 35]. Considering that CYP proteins locate to the 
yeast ER, the entire CYP cDNA can be expressed without truncating the sequence 
that encodes the N-terminus, as it is necessary for efficient CYP expression in 
Escherichia coli [36]. Third, although CYPs are differentially degraded [37], they are 
sufficiently stable to activate carcinogens for extended time duration, circumvent-
ing problems of transient or variable expression observed in cultures derived from 
cryopreserved hepatocytes. Based on genotoxic endpoints that can be easily scored, 
it is possible to phenotype CYP polymorphisms and to determine whether their 
substrate specificities are altered.
2.1 Mammalian CYP expression in budding yeast
Yeast has been an attractive organism for the expression of heterologous proteins 
and useful for characterizing biochemical properties of mammalian cytochrome 
P450 properties. Its success at producing large quantities of human proteins, such as 
human insulin [38], has largely been due to an advanced understanding of both the 
transcriptional and translational machinery of eukaryotic gene expression, includ-
ing well-characterized transcriptional promoters and terminators [39]. Constitutive 
promoters for expression include ADH1, GAPDH, PGK1, TPI, ENO, PYK1, and 
TEF, while inducible promoters include GAL1–10, CUP1, PHO5, and ADH [40]. 
Expression can be further amplified by high-copy-number vectors or modulated 
by single-copy vectors, which have been well-described in the literature [34]. Oeda 
et al. [41] expressed rat CYP2E1cDNA using the constitutive ADH1 promoter and 
the phosphoglycerol kinase (pGK) terminator using a high-copy-number vector. 
5Genotoxic Assays for Measuring P450 Activation of Chemical Mutagens
DOI: http://dx.doi.org/10.5772/intechopen.90356
The ability to bind carbon monoxide (CO) confirmed the presence of the recombi-
nant protein. Characterization of human CYP3A4 produced in yeast underscored its 
broad substrate specificity [42, 43]. Additional in vitro studies involved expressing 
either human or rat cDNAs of CYP1A1, CYP2E1, CYP1A2, and CYP1B1 and con-
firming their biochemical properties [43]. A list of CYPs that have been expressed 
in yeast is shown in Table 1.
While inserting mammalian cDNA into expression vector by standard molecular 
techniques of subcloning can be tedious, many mammalian CYP cDNAs are now 
commercially available in gateway compatible DNA vectors. Gateway compatible 
vectors contain small segments of DNA, referred to as attP and attB sites, which 
CYP gene Expression 
vector
Enzymatic assays Carcinogen 
activation
Genotoxic 
assays/
biosensor 
reporter
References
CYP1A1 pSB229, 
pRS424 
CYP1A1
EROD1 BaP-DHD4 HR9, 
mutation, 
growth 
curves
[46, 50, 51]
AFB15 HR, 
mutation, 
growth 
curves
Yfp-Rad51 
foci
[46, 50, 51]
IQ6 Growth 
curves
[51]
CYP1A2 pCS316, 
pAAH5N
EROD,MROD2, 
LND3
AFB1 HR, 
mutation
Yfp-Rad51 
foci
[43, 50]
MeIQx7 HR [87]
IQ HR [87]
CYP1A2/
NAT2
pGP100 MROD, SMZ assay IQ , MeIQx, 
MeIQ
HR [87]
CYP1B1 pYES2, 
pAG24
EROD AFB1, BaP-DHD [111]
CYP2A6 pAAH5N LND [43]
CYP2B6 pAAH5N,
pESC-URA3
LND, 
7-ethoxycoumarin-
3-carbonitrile 
deethylation
N-nitrodimethyl 
amine
[43]
AFB1 RAD54-
GFP
[71]
CYP2C8 pAAH5N LND [43]
CYP2C9 pAAH5N Lauric acid 
(omega-1)-
hydroxylation
[43]
CYP2C18 pAAH5N LND [43]
CYP2D6 pAAH5N, 
pESC-URA3
LND, debrisoquine 
4-hydroxylation, 
ethoxycoumarin-
3-carbonitrile 
deethylation
RAD54-
GFP
[71]
Genotoxicity and Mutagenicity - Mechanisms and Test Methods
6
flank the insert and are substrates for site-specific recombinases [44]. CYP cDNAs 
inserted into donor vectors can then be transferred into recipient yeast expression 
vectors by mixing the appropriate DNAs with recombinases; these reagents are com-
mercially available and eliminate protocols using restriction enzymes and ligase. 
Recipient yeast expression vectors include multi-copied vectors as well as inducible 
and constitutive promoters [44]. An additional mechanism to increase CYP expres-
sion is to enhance translation of mRNA; Kozak sequences can be inserted into DNA 
sequences that encode mRNA upstream untranslated regions (UTR) [45].
2.2 Assays for detecting CYP expression
Enzymatic assays to measure CYP activity have often relied on converting non-
fluorescent substrates into fluorescent products or measuring products by high-per-
formance liquid chromatography (HPLC). Fluorescent products can be measured 
in a 96-well plate on a plate reader. The assay mix involves NADPH or a NADPH-
regenerating system, such as glucose dehydrogenase; the pH is critical so the assay 
mix must be carefully buffered [46]. Microsome preparations of cytochrome 
P450s from yeast involve lysing cells using glass beads, centrifugation to remove 
debris, and precipitating microsomes using NaCL and polyethylene glycol [47]. 
These microsome fractions can be further concentrated by ultracentrifugation and 
stored at −80°C for extended time periods. Activity measurements are expressed 
as picomole of product per minute per mg protein; more precise measurements of 
CYP protein concentration can be obtained by measuring absorbance at a 450nm 
wavelength after the sample has been exposed to CO.
To optimize mammalian enzyme activity in yeast cells, it is necessary to 
co-express the CYP, human oxidoreductase (hOR), and cytochrome B (cytB) 
CYP gene Expression 
vector
Enzymatic assays Carcinogen 
activation
Genotoxic 
assays/
biosensor 
reporter
References
CYP2E1 pAAH5N Lauric acid 
(omega-1)-
hydroxylation
[43]
CYP3A4 pAAH5N, 
pMA34, 
pESC-URA3
Diclorofenac, 
testosterone 
6β-hydroxylation, 
ethoxycoumarin-
3-carbonitrile 
deethylation
AFB1 HR, growth 
curves
RAD54-
GFP, 
RNR3-GFP
[67, 71]
IQ [67]
BaP8 RAD54-
GFP
[71]
1Ethoxyresorufin deethylase (EROD).
2Methyoxyresorufin demethylase (MROD).
3Lidocaine N-deethylation (LND).
4Benzo[a]pyrene 7,8, dihydrodiol (BaP-DHD).
5Aflatoxin B1 (AFB1).
62-Amino-3-methylimidazo-[4,5-f ]quinoline (IQ ).
72-Amino-3,8-dimethylimidazo-[4,5-f ]quinoxaline (MeIQx).
8Benzo[a]pyrene,
9homologous recombination (HR).
Table 1. 
Human P450 genes that have been expressed in yeast.
7Genotoxic Assays for Measuring P450 Activation of Chemical Mutagens
DOI: http://dx.doi.org/10.5772/intechopen.90356
oxidoreductase [48]. Because yeasts contain endogenous oxidoreductases [49], 
the overexpression of the hOR is not a requirement for expression of all CYPs but 
generally does enhance CYP activity. For example, expression of hOR is required to 
measure CYP1A1 but not CYP1A2 activity [49, 50]. Other investigators have shown 
that the insertion of hOR directly in the genome is sufficient to obtain extracts to 
monitor the activity of CYP1A1 and CYP3A4 [51, 52].
3. Genotoxic assays
To be proven positive, the genotoxic effects must be dose dependent and 
reproducible. Examples of genotoxic agents include those that directly bind to or 
modify DNA, induce reactive oxygen species (ROS), and inhibit topoisomerases 
and other proteins involved in DNA metabolism. These genotoxic agents can cause 
a multiplicity of DNA insults, including DNA base modifications, DNA adducts, 
cross-links, and single- and double-strand breaks. Different DNA damage insults 
can quantitatively result in different biological endpoints. For example, a single 
double-strand break is sufficient to initiate genome rearrangements and trigger 
cell cycle arrest [53], while other types of DNA damage, such as particular cross-
links and abasic sites, are effectively tolerated by DNA replication bypass pathways 
(for reviews, [54]). These replication bypass pathways include template switching 
and error-free polymerase switch mechanisms that may not trigger cell cycle 
arrest or a DNA damage response [54]. Thus, there is a need for measurements 
of multiple genotoxic endpoints to accurately assess the biological effect of any 
genotoxin.
Genotoxic endpoints include direct measurements of DNA damage and DNA 
adducts, reporter assays that detect transcriptional induction of DNA damage-
inducible genes, growth assays for monitoring fitness [55], and plate assays for 
detecting recombination and mutations. Reporter assays involve yeast strains that 
contain a DNA damage-inducible promoter linked to a protein tag whose fluo-
rescence or activity can be readily detected. Examples of proteins whose activity 
can be readily measured include lacZ, encoding β-galactoside, and GUS encod-
ing β-glucuronidase (reviewed in [1]). Signaling assays have been successfully 
employed for high-throughput analysis using 96-well plate platforms and flow 
cytometry. The plate assays can elucidate endpoints of genotoxicity, while reporter 
assays can identify a chemical as a genotoxic assay and establish minimum concen-
trations in which a chemical may have an effect. Plate assays have been successful in 
measuring multiple genotoxic endpoints, including mutation [56, 57], homologous 
recombination [2], retrotransposition [58], and gross chromosomal rearrangements 
[59]. Plate assays involve inoculating engineered yeast strains on selective media, 
and after an incubation period, selected colonies can be counted and viability can 
be measured on nonselective media.
Direct assays to measure DNA strand breaks include chromosomal DNA 
integrity by pulse-field electrophoresis [60] and by single-cell comet assays 
[61]. Pulse-field electrophoresis has been successfully used to monitor repair of 
radiation-induced double-stranded DNA and the integrity of rDNA. Single-cell 
comet assays involve exposing cells to chemical agents, embedding them in agarose, 
subjecting them to an electric field, and staining for DNA [61]. Fragmented DNA 
migrates faster in an electric field, and the fragmented DNA appears as a “tail” [62]. 
Chemical DNA adducts, such as AFB1-N7-guanine adducts, can be detected using 
high-performance liquid chromatography, mass spectrometry (LC/MS–MS) after 
cells have been lysed and DNA has been extracted and acid hydrolyzed [63, 64].
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3.1 Reporter assays
Reporter assays with fluorescent readouts are useful in detecting cells that have 
been exposed to genotoxins that induce DNA damage. Fluorescence can be moni-
tored using 96-well plates, rendering it possible to perform high-throughput analy-
sis. Fluorescent cells can also be imaged using flow cytometry platforms, such as 
the Amnis Image Stream [65], which can also measure cell type, DNA content, and 
cell cycle stages. DNA damage reporters include RAD54-GFP [66], RNR3-GFP [67], 
and HUG1-GFP [68]. These fusions have been widely used because signal-to-noise 
ratio is very low. RAD54 is a DNA repair gene that functions in recombinational 
repair of double-strand breaks; GreenScreen assay (GSA) utilizes the RAD54-GFP 
reporter in high-throughput screens [69]. The RadarScreen assay uses a RAD54 
β-galactosidase reporter construct in which β-galactosidase cleaves the substrate 
into galactose and luciferin [70]. HUG1 encodes an inhibitor of ribonucleotide 
reductase, while RNR3 encodes the large subunit of ribonucleotide reductase that is 
specifically induced because of DNA damage [71]. The fluorescent markers can be 
enhanced using yEGFP, engineered for yeast codon bias. While RNR3 and RAD54 
promoters have been extensively used, promoters for PLM2, encoding a puta-
tive transcription factor, and for DIN7, encoding a mitochondrial nuclease, have 
been recently reported to be more inducible for detection of genotoxins [1]. These 
studies indicate that there are robust reporters with sensitive readouts for screening 
genotoxins.
Genotoxins that inhibit histone deacetylases, such as Sir2, can be detected using 
reporters that detect expression of the silent mating-type locus (HML). In a strain 
containing one such fluorescent reporter, the cre recombinase gene was placed 
within the HML locus, while loxP recombination sequences were positioned flank-
ing an intervening sequence that occluded a promoter from transcribing the GFP 
reporter [72]. Transient expression of cre triggers recombination at the loxP sites 
and excision of the intervening sequence, thus allowing the promoter to transcribe 
GFP. While this assay does not directly measure genotoxicity, inhibition of Sir2 can 
trigger rDNA instability [73].
3.2  Plate assays for detecting recombination, mutation, and microsatellite 
instabilities
Plate assays that detect mutation and recombination endpoints consist of 
selections or screens for prototrophic or drug resistance markers. Several genotoxic 
endpoints can be determined by color phenotypes. For example, Ade+ colonies are 
white, while ade2 and ade3 colonies are red. Recombination between two non-
revertible ade2 and ade3 alleles can be observed by visualizing colony sectors [74]. A 
similar scheme can also be employed for detecting mutations that affect the SUP4-o 
function in suppressing ade2 nonsense alleles [75]. By choosing different proto-
trophic selections for individual assays, combinations of these assays in a single 
strain can facilitate measurements for multiple genotoxic endpoints, including 
mutation and recombination. Typically, the strains are diploids. Prototype strains 
included D7, which allows for measuring multiple number of mutation event [57]. 
For designing strains to detect DNA damage-associated homologous recombination 
between heteroalleles or between repeated sequences (ectopic recombination), gene 
editing and one-step gene replacement [76] rendered it possible to position non-
revertible markers in tandem, on homologs or on nonhomologous chromosomes. 
For example, ade2-a and ade2-n alleles can be used for measuring intrachromatid 
gene conversion and recombination between homologs [74]. By deleting the 
entire wild-type gene, and positioning overlapping gene fragments at preselected 
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positions in the yeast genome, frequencies of rare recombinants can be selected. For 
example, his3 gene fragments, his3-Δ3’ and his3-Δ5’, can be positioned at predeter-
mined positions in the genome and His+ recombinants for measuring frequencies 
of unequal sister chromatid exchange (SCE), translocations, and intrachromatid 
deletions [77]. Schiestl et al. [2] used a diploid strain that contained a his3 deletion 
on one chromosome and a disrupted HIS3 gene to measure intrachromatid recom-
bination; this strain has also been referred to as the “DEL” assay. The complete dele-
tion of HIS3, his3-Δ200, also enabled a selection for monitoring Ty1 transposition. 
Boeke et al. [78] inserted an artificial intron in an inverted orientation within HIS3 
contained within Ty1 so that His+ cells could only result when retrotransposition 
of Ty1 occurred. Transposition of HIS3, as well as chromosomal rearrangements 
generated by recombination between his3 fragments, can be physically character-
ized by pulse-field gel electrophoresis (Figure 2).
A plate assay that detects gross chromosomal rearrangements was devised in 
haploid strains. This assay involved two drug selection markers, CAN1 and URA3, 
where the URA3 gene was inserted near CAN1 on the right arm of chromosome V at 
the HXT13 locus; the right arm of chromosome V is not required for viability [79]. 
CAN1 encodes the arginine permease gene and confers sensitivity to the arginine 
analog, canavanine, while URA3 confers sensitivity to the drug 5-fluoro-orotic 
acid (FOA). Since the frequencies of spontaneous CanR FOAR is extremely low, 
3.5 × 10−10 [79], most CanR FOAR selected colonies contain gross chromosomal rear-
rangements, in which deletions, translocations, or multiple rearrangements have 
Figure 2. 
Recombination assays that are used in detecting DNA damage-associated recombination. The HIS3 gene is 
shown with an arrow and feathers. The fragment that lacks the 3’ end is shown without the arrow; the fragment 
that lacks the 5’ end is shown without the arrow. The two fragments share approximately 300 bp of homology. 
The Roman numerals represent different chromosomes. The oval represents the centromere. For simplicity, the 
left arm of the chromosomes is not shown. In the transposition assay, an artificial intron (AI) is inserted in the 
HIS3 so that it is in the opposite orientation as the HIS3 promoter. For HIS3 to be expressed, the Ty1 element 
must first be transcribed, the AI spliced from the mRNA, and the mRNA reverse transcribed and integrated 
into the chromosome.
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occurred that conferred resistance to both drugs. However, because drug sensitivity 
is dominant, CanR FOAR recombinants are detected in haploid strains.
By combining different gene fragments and alleles, as well as drug-resistant 
markers, multiple genotoxic endpoints, including heteroallelic recombination, 
unequal SCE, translocations, and mutation, can be measured within a single strain. 
As an example, Fasullo et al. [64] designed a haploid strain useful in measuring 
frequencies of DNA damage-associated mutations and unequal SCE after exposure 
to AFB1. A useful diploid strain was also engineered for measuring frequencies of 
DNA damage-associated homolog recombination between heteroalleles and ectopic 
recombination between gene fragments on nonhomologous chromosomes [64]. 
While these plate assays can elucidate genotoxic endpoints, their noise-to-signal 
ratio can vary, depending on the frequencies of spontaneous events. While frequen-
cies of spontaneous mutations at CAN1 are relatively low, 10−6, the frequencies of 
spontaneous recombinants can vary from 10−4 to 10−10 [79]. Higher frequencies of 
spontaneous recombination are generally associated with intrachromosomal events, 
while lower frequencies of spontaneous recombination are associated with ectopic 
recombination between gene fragments on nonhomologous chromosomes. The 
lower the spontaneous frequency infers the higher the signal-to-noise ratio; thus, 
DNA damage-associated recombinants may be identified at exposures to lower 
concentrations of genotoxins.
While there are a multitude of plate assays for detecting nuclear genotoxic stress, 
there are fewer assays for detecting mitochondrial genotoxic stress. In part this is 
due to few auxotrophic markers, the high copy number (50–100) of mitochondrial 
DNA, and random segregation of mitochondria in mitosis [80]. Nonetheless, 
mitochondrial deficient yeast can be detected by the petite colony phenotype and 
the color phenotype of Ade− mutants that appear pink or white in contrast to red on 
YPD media that is limiting in adenine [81]. In addition, Sia et al. [82] constructed 
a mitochondrial reporter gene arg8(m). This reporter has poly(AT) or poly(GT) 
out-of-frame insertions within the coding sequence so that Arg+ prototrophs can be 
selected resulting from microsatellite instability.
While the plate and reporter assays are useful for detecting genotoxins and elu-
cidating their mechanisms, yeast lacks many metabolic activities found in metaboli-
cally competent mammalian cells. Some protocols to activate carcinogens use rat 
S9 fractions, which may produce more metabolites than human CYPs, [83–85]. To 
mitigate this deficiency, human CYPs have been introduced into the strains for both 
plate assays and reporter assays. For example, Bui et al. [71] expressed CYP1A2, 
CYP2C9, CYP3A4, and CYP2D6 in a strain that monitors RAD54-GFP. Sengstag 
et al. [50] and Fasullo et al. [64, 67] have expressed CYP1A1, CYP1A2, and 
CYP3A4 in strains that monitor translocations, mutations, and unequal SCE. Guo 
et al. [86] have introduced CYP1A2 into multiple yeast mutants to determine AFB1 
resistance. Paladino et al. [87] have expressed CYP1A2 and NAT2 to activate a 
variety of heterocyclic aromatic amine in strains to measure homology-directed 
translocations. Both CYP-containing reporter strains and plate assay strains expand 
the repertoire of chemicals that can be tested by high-throughput analysis.
4. Chemicals that test positive in the yeast strains
Overall, thousands of chemicals have been tested using either one or both plate 
and reporter-based assays [1]. Van Gompel et al. [69] report on the screening of 
2698 proprietary compounds and pharmaceuticals using the GreenScreen assay; 
of these compounds, approximately 7% of those 164 that test positive are also 
positive in the Ames assays, demonstrating that agents that test positive represent 
11
Genotoxic Assays for Measuring P450 Activation of Chemical Mutagens
DOI: http://dx.doi.org/10.5772/intechopen.90356
overlapping groups. Screens of industrial, environmental, and food carcinogens 
have used multitude tester strains, including the “DEL” and transposition assays 
[88]. Chemical agents include those that directly inflict DNA damage, induce ROS, 
inhibit DNA metabolic function, and alter histone modification. Metallic nanopar-
ticles also test positive in several assays although their mechanism of action has yet 
to be determined [89]. Whereas almost all chemicals that test positive in plate assays 
will also test positive in reporter assays, the converse is not necessarily true. These 
results demonstrate that several reporter assays are capable of high-throughput 
screening and can identify multiple compounds that test positive in additional 
genotoxic assays.
Several agents that cause direct DNA damage, such as base pair damage, cross-
links, DNA adducts, or DNA strand breaks, test positive in reporter assays and may 
test positive in one or more of the plate assays [90]. For example, alkylating agents, 
such as methyl methane sulfonate (MMS), increase frequencies of mutations, 
recombination, gross chromosomal rearrangements (GCRs), and retrotransposi-
tion. Interestingly, alkylating agents also test positive in enhancing expression 
of the silent mating-type locus HML [91]. Other types of alkylating agents, such 
as 1-methyl-3-nitro-1-nitrosoguanidine (MNNG) and ethyl methane sulfonate 
(EMS), test positive in reporter and mutation assays; however, frequencies of DNA 
damage-associated sister chromatid exchange events are only modestly increased 
[58, 64, 67]. Cross-linking agents, such as cis-platinum and other UV-mimetic 
agents, also tend to be positive in a broad range of reporter assays, including those 
for retrotransposition and homologous recombination [90]. Finally, radiomimetic 
agents that cause strand breaks, such as zeocin and bleomycin, test positive in many 
reporter assays as well as assays for gross chromosomal rearrangements and trans-
locations [59]. These studies demonstrate that while a subset of alkylating agents 
manifest broad genotoxicity, frequencies of DNA damage associated with GCRs 
and translocations manifest the highest increase after exposure to agents that cause 
double-strand breaks.
Chemical agents that inhibit DNA metabolic and repair functions are often 
genotoxic. These include camptothecin, which inhibits topoisomerase I and 
causes single-strand breaks and replication fork collapse, and hydroxyurea, which 
blocks DNA replication by inhibiting ribonucleotide reductase and thus depleting 
deoxynucleotides [92, 93]. Other metabolic inhibitors include those that inhibit 
dihydrofolate reductase, and result in uracil incorporation also tests positive in a 
broad range of plate assays, including those for sister chromatid recombination, 
heteroallelic recombination, and translocations. Cd2+ exposure inhibits mismatch 
repair [94] and is also genotoxic [95]. These studies indicate that genotoxins include 
chemicals that may directly inhibit critical enzymes in DNA metabolism.
While chemicals are individually screened in many plate and reporter assays, 
combination of chemicals can also enhance DNA damage or enhance mutagenesis. 
An example includes intercalating agents, such as acridine and bleomycin; the 
insertion of acridine in the DNA helix facilitates bleomycin access to the minor 
groove and subsequent strand breakage [96]. In addition, by inhibiting mismatch 
repair, Cd2+ exposure facilitates the mutagenesis by alkylating agents [94]. These 
studies indicate that combinations of genotoxins can accelerate genome instability.
Mitochondria are particularly prone to DNA intercalating agents, and agents 
that cause oxidative damage, and reduce or cause imbalance to deoxynucleotide 
pools [97]. ROS-associated damage in the mitochondrial genome, associated with 
oxidative phosphorylation, is not repaired by nucleotide excision repair (NER) 
but by base excision repair (BER) [1]. In addition, mitochondrial DNA is circular 
and therefore is more prone to DNA intercalating agents that can cause topological 
stress, such as ethidium bromide and acridine compounds [98]. Several fluorescent 
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dyes can also induce mitochondrial DNA damage [1]. Replication of mitochon-
drial DNA depends on a single polymerase, DNA polymerase γ [99]. Therefore, 
chemicals that inhibit mitochondrial DNA polymerase, such as dideoxynucleoside 
antiretrovirals, are often genotoxic [100]. Thus, yeast screens that detect mitochon-
drial DNA damage are useful in screening off-target effects on antiretroviral agents.
CYP allele Amino acid 
substitution
Enzyme assay Disease 
association
Genotoxic 
endpoints
Reference
CYP1A1*2C 1462V 
(near heme 
binding site)
EROD1 Lung, 
prostate and 
breast cancer
Rad51 foci, 
growth 
curves, HR4
[51]
CYP1A1*4 T461N 
(near heme 
binding site)
EROD Endometrial 
and lung 
cancer
Rad51 foci, 
growth 
curves, HR
[51]
CYP1A2*5 C406Y MROD2 ND Rad51 foci, 
growth 
curves, HR
[63]
CYP1A2*3 D348N MROD ND Rad51 foci, 
growth 
curves, HR
[63]
CYP1A2*4 I386F MROD ND Rad51 foci, 
growth 
curves, HR
[63]
CYP1B1*7 R48G; 
A119S; 
L432V; 
A443G
BaP-DHD 
epoxidation3
L432V has 
an increased 
risk for 
prostate and 
lung
NT [110]
CYP1B1*12 G61E BaP-DHD 
epoxidation
Glaucoma NT [110]
CYP1B1*18 G365W BaP-DHD 
epoxidation
Glaucoma NT [110]
CYP1B1*23 P437L BaP-DHD 
epoxidation
Glaucoma NT [110]
CYP2E1 Benzene 
hydroxylation
NT [111, 112]
CYP2E1*2 R76H Benzene 
hydroxylation
Bladder 
cancer 
(reduced 
risk in Asian 
population)
NT [111, 112]
CYP2E1*3 V389I Benzene 
hydroxylation
Bladder 
cancer 
(reduced 
risk in Asian 
population)
NT [111, 112]
CYP2E1*4 V179I Benzene 
hydroxylation
Bladder 
cancer
NT [111, 112]
1Ethoxyresorufin deethylase (EROD).
2Methyoxyresorufin demethylase (MROD).
3Benzo[a]pyrene 7,8, dihydrodiol (BaP-DHD).
4Homologous recombination (HR).
ND = not determined, NT = not tested.
Table 2. 
Cytochrome P450 polymorphisms expressed in yeast.
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While many carcinogens are directly genotoxic, others require metabolic activa-
tion. The list of CYPs expressed in yeast and chemical agents that are activated are 
listed in Table 2. The agents tested include polyaromatic hydrocarbons (BaP-DHD), 
mycotoxins (AFB1), and heterocyclic aromatic amines (2-amino-3,8-dimethy-
limidazo-[4,5-f]quinoxaline (MeIQx), 2-amino-3, 4-dimethylimidazo-[4,5-f]
quinoline (MeIQ ), and 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ )). Bui et al. 
[71] introduced human CYPs into strains to measure induction of GFP using the 
reporter RAD54-GFP. Li et al. [52] used a sensitive fluorimetric assay to measure 
inhibition of secreted dextranase; the assay consists of strains expressing Lipomyces 
kononenkoae amylase, CYP3A4, and hOR [52]. The amylase-expressing strain 
detected AFB1 at 2 ng/ml and the T-2 mycotoxin [52].
Activation of these compounds has also been determined by measuring DNA 
recombination and mutation; DNA adducts have been detected after AFB1 and BaP-
DHD exposure. Frequencies of mutations and recombination may be differentially 
elevated by CYP-activated genotoxins. For example, CYP1A1 and CYP1A2 activation 
of AFB1 in yeast results in a 20–50-fold increase in the stimulation of recombination 
but only a fivefold increase in mutation frequency [50]. However, CYP1A1-mediated 
activation of BaP-DHD results in a higher activation of mutation but somewhat 
diminished activation of recombination [50]. Because the background frequency is 
so low, the CYP1A2-expressing strains containing the translocation assay have been 
particularly useful in detecting the DNA damage-associated recombinants [50].
5.  Yeast mutants that exhibit enhanced phenotypes after genotoxin 
exposure
Various gene mutations can increase the signal-to-noise ratio. Typically, these 
mutations are encoded in cells lacking cell wall components, nucleotide or base 
excision repair genes, and xenobiotic transporters. Strains that lack cell wall 
components and xenobiotic transporters include pdr5, snq2, cwp1, cwp2 [1]. Strains 
that lack NER and BER genes include those mutated in rad1 and mag1, respectively. 
Several strains also contain deletions in yap1 [101], a gene that encodes a transcrip-
tion factor that confers transcriptional induction among antioxidant genes, such as 
TRX2, and is required for H2O2 and Cd resistance [102]. Several strains have been 
designed so that multiple genes are mutated to enhance the genotoxic signal. Wei 
et al. [103] have used a septuplet deletion mutant (snq2, prd5, cwp1, cwp2, yap1, 
rad1, mag1) in combination with an integrated HUG1-yEGFP reporter as a very sen-
sitive detection for multiple chemicals. Deletion of NER genes has been successful 
in enhancing DNA damage-associated recombination after exposure to BaP-DHD 
and AFB1 [104].
While deleting DNA repair genes may enhance signal-to-noise ratios for reporter 
assays and some recombination and mutation assays, particular DNA repair defects 
may decrease frequencies of DNA damage-associated recombination in particular 
plate assays. For example, blocking nonhomologous end joining (NHEJ) may 
increase homologous recombination initiated by double-strand breaks in haploid 
strains, while decreasing DSB-associated translocations [105]; the likely explana-
tion is that competing DNA repair pathways for recombination are differentially 
favored for homologous vs. NHEJ. Rad1 mutations may confer lower DNA damage-
associated recombination in assays, such as the “DEL” assay [106]. The rad1 mutants 
are defective in the Rad1/Rad10 nuclease; this nuclease cleaves 3′ blocked termini 
and is important in single-strand annealing mechanisms. However, other rad 
mutants that are deficient in NER, such as rad4, may be suitable for observing both 
enhanced DNA damage-associated recombination and mutations [67].
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One strategy has been to use DNA repair mutants that are knocked out in multiple 
DNA repair pathways to assess the genotoxicity of chemicals. For example, rad4 rad51 
double mutants, which are deficient in both NER and in recombinational repair, are 
synergistically more sensitive to UV and many chemical UV-mimetic agents. By intro-
ducing CYP genes into the rad4rad51, the strain also becomes synergistically more 
sensitive to AFB1 as well as extremely sensitive to other PAHs and HAAs [51, 67].
Mechanistic insights into how genotoxic agents stimulate chromosomal insta-
bility are also gained from studies of checkpoint genes. For example, deleting the 
RAD9-mediated checkpoint which triggers G2 arrest confers higher levels of DNA 
damage-associated recombination (translocations) after cells are exposed to X-rays 
and radiomimetic agents that cause breaks such as MMS and bleomycin. Enhanced 
translocation frequencies are also observed after rad9 cells are exposed to camp-
tothecin, an inhibitor of topoisomerase I. On the other hand, rad9 deletion does 
not confer higher levels of recombination associated with agents, such as 4-nitro-
quinoline oxide (4-NQO), that cause bulky DNA damage [107]. These observations 
suggest that agents that stimulate DNA break formation may be identified if they 
enhance recombination in rad9 mutants.
6. Phenotyping CYP polymorphisms in budding yeast
The CYP genes are highly polymorphic, and particular polymorphisms have 
been identified as risk factors for cancer [13, 22, 108] and glaucoma [109]. While 
yeast strains are useful in elucidating the genotoxicity of P450-activated carcino-
gens, yeast strains are also useful in characterizing human CYP polymorphisms. 
CYP1A1, CYP1A2, CYP1B1, and CYP2E1 polymorphisms have been studied in yeast 
[51, 63, 110–112]. The polymorphisms can be characterized in a number of ways: 
(1) substrate specificity, (2) activity with a defined substrate, (3) genotoxic end-
points, and (4) DNA adducts. For example, CYP1A2 polymorphisms have different 
affinities for heterocyclic aromatic amines; these polymorphisms have been also 
characterized by their ability to bioactivate aflatoxin B1. Activity assays have been 
performed for polymorphisms in CYP2E1, CYP1B1, CYP1A1, and CYP1A2 [51, 63, 
110, 111]. In general activity assays agree with those performed when assays are 
performed in other model systems, such as E. coli [113].
Several CYP1A1 polymorphisms are present in a significant percentage of 
the population and may be risk factors for lung and breast cancer. For example, 
CYP1A1 I462V and CYP1A1 T461N have been correlated to have higher incidence 
of lung, breast, and endometrial cancer [114, 115]. A plausible hypothesis is that 
CYP1A1 I462V and CYP1A1 T461N are more active in converting breast- and 
lung-associated carcinogens into genotoxins. However, another model suggests that 
CYP1A1 is protective, since CYP1A1 knockout mice actually have a higher incidence 
of carcinogen-associated cancer [10]. Freedland et al. [51] measured multiple 
genotoxic endpoints in yeast strains expressing CYP1A1 I462V after exposure to 
multiple carcinogens and interestingly found a reduced level of bioactivation. This 
is consistent with a model that CYP1A1 may actually be protective and compete 
with other CYPs that convert carcinogens into active genotoxins [10].
7. Implications for higher eukaryotes
The ability to perform high-throughput screening to identify genotoxins using 
yeast strains containing sensitive reporter facilitates the identification of chemicals 
that merit more detailed and expensive studies. While yeast reporter strains can 
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be useful for high-throughput identification of genotoxins, yeast plate assays and 
genetics can elucidate mechanisms. Genotoxins that stimulate recombination 
and retrotransposition in yeast are likely to stimulate genetic instability in higher 
eukaryotes. Indeed, many recombinagens that have tested positive in yeast also test 
positive in higher eukaryotes. An excellent example is AFB1, which is also a recom-
binagen in human cell lines [116].
8. Conclusions and future directions
Yeast assays for detecting genotoxins and identifying genotoxic mechanisms 
are urgently needed to screen a multitude of industrial chemicals, pesticides, and 
pharmaceuticals. These assays have already been successful in screening thousands 
of chemicals, aiding in our understanding of genotoxic mechanisms. These assays 
have been further empowered by the technology to introduce human phase I and 
phase II metabolism in yeast cells. While the reporter assays enable high-throughput 
studies for rapid identification of genotoxins, the multitude of plate assays enables 
mechanistic studies to elucidate genotoxic mechanisms. The future challenge is to 
combine many of the reporters and plate assays so that both the screening and the 
mechanistic studies can be expedited.
Currently, the mechanisms of many chemical agents, which increase cancer risk, 
are unknown. Of particular interests are many small-molecule toxicants present in 
industrial workplace or which are extensively used in agriculture. How exposure to 
mixtures of these chemicals increases genotoxicity will be important in assessing 
risk factors to human health.
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